• Ryo Naito, Katsumi Miyauchi, Manabu Ogita, Takatoshi Kasai, Yuko Kawaguchi, Shuta Tsuboi, Hirokazu Konishi, Shinya Okazaki, Takeshi Kurata, and Hiroyuki Daida.
• Department of Cardiovascular Medicine, Juntendo University, Tokyo, Japan.
• J Cardiol. 2014 Feb 1; 63 (2): 106-11.

BackgroundAdmission glucose levels have proven to be a predictor in patients with acute myocardial infarction and elevated glycosylated hemoglobin A1c (HbA1c) is associated with an increased risk of cardiovascular disease, even in patients without diabetes. However, the effect of both admission glucose and HbA1c levels on clinical outcomes in non-diabetic patients with acute coronary syndrome (ACS) has not been fully elucidated. We evaluated the combined effect of admission glucose and HbA1c values on long-term clinical outcomes in non-diabetic patients with ACS treated with percutaneous coronary intervention (PCI).Methods And ResultsThis was an observational study of 452 consecutive non-diabetic patients with ACS who underwent PCI between January 1997 and December 2006. The patients were assigned to four groups according to the median values of admission glucose and HbA1c. The primary endpoint comprising a composite of all-cause death and non-fatal MI was compared among the four groups. The primary endpoint occurred in 13.3% of the participants during a median follow-up period of 4.7 years. The cumulative incidence rate of primary endpoint significantly differed among the groups (p=0.048). Multivariable Cox regression analysis showed that the combination of elevated admission glucose and HbA1c was independently associated with long-term clinical outcomes.ConclusionsCombined admission glucose and HbA1c values were independently associated with clinical outcomes in non-diabetic patients with ACS treated with PCI.Copyright © 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

24 keywords...

hide…